• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma.

作者信息

Trojan A, Montemurro M, Kamel M, Kristiansen G

出版信息

Ann Oncol. 2009 Nov;20(11):1898-9. doi: 10.1093/annonc/mdp431. Epub 2009 Sep 11.

DOI:10.1093/annonc/mdp431
PMID:19748901
Abstract
摘要

相似文献

1
Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma.
Ann Oncol. 2009 Nov;20(11):1898-9. doi: 10.1093/annonc/mdp431. Epub 2009 Sep 11.
2
Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.胶质母细胞瘤中血小板衍生生长因子受体-α、-β、c-kit、c-abl和精氨酸酶蛋白的免疫组织化学分析：对甲磺酸伊马替尼治疗患者选择的潜在意义
J Neurooncol. 2006 Jan;76(2):105-9. doi: 10.1007/s11060-005-4570-9.
3
Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.评估甲磺酸伊马替尼对复发或难治性KIT阳性或PDGFR阳性肉瘤有效性的多中心II期试验。
J Orthop Sci. 2010 Sep;15(5):654-60. doi: 10.1007/s00776-010-1506-9. Epub 2010 Oct 16.
4
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.甲磺酸伊马替尼（格列卫）在妇科肿瘤学组 II 期试验中对复发性或持续性子宫癌肉瘤妇女的疗效和安全性以及 c-Kit 和 PDGFR-β的免疫组织化学表达。
Gynecol Oncol. 2010 May;117(2):248-54. doi: 10.1016/j.ygyno.2010.01.002. Epub 2010 Feb 26.
5
KIT and PDGF as targets.
Cancer Treat Res. 2004;120:117-27. doi: 10.1007/1-4020-7856-0_7.
6
Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.伴有FIP1L1-PDGFRA重排的单核细胞性髓系肉瘤对伊马替尼单药治疗的完全缓解
Br J Haematol. 2014 Jun;165(5):583. doi: 10.1111/bjh.12742. Epub 2014 Jan 24.
7
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].[原癌基因Fip1样蛋白1/血小板衍生生长因子受体α作为伊马替尼治疗高嗜酸性粒细胞综合征和慢性嗜酸性粒细胞白血病患者的靶点。对发病机制和治疗的新见解]
Pol Arch Med Wewn. 2005 May;113(5):490-7.
8
Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
Cancer Treat Res. 2004;120:129-50. doi: 10.1007/1-4020-7856-0_8.
9
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.甲磺酸伊马替尼可诱导FIP1L1-PDGFR-a阳性特发性嗜酸性粒细胞增多综合征实现完全分子缓解。
Haematologica. 2004 Feb;89(2):236-7.
10
Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.甲磺酸伊马替尼作为表达血小板衍生生长因子受体α的复发性或转移性宫颈癌二线治疗药物缺乏疗效。
Int J Gynecol Cancer. 2009 Dec;19(9):1632-7. doi: 10.1111/IGC.0b013e3181a80bb5.

引用本文的文献

1
Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.阿帕替尼在未经治疗或化疗难治性软组织肉瘤患者中的疗效与安全性：一项多中心2期试验
Ann Transl Med. 2022 Sep;10(18):981. doi: 10.21037/atm-22-4229.
2
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.基于多组学框架的子宫癌肉瘤的分子分类和亚型特异性药物敏感性研究。
Cancer Biol Ther. 2019;20(2):227-235. doi: 10.1080/15384047.2018.1523853. Epub 2018 Oct 25.
3
Potential Therapeutic Targets in Uterine Sarcomas.
子宫肉瘤的潜在治疗靶点
Sarcoma. 2015;2015:243298. doi: 10.1155/2015/243298. Epub 2015 Oct 21.
4
Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.子宫内膜间质肿瘤：酪氨酸激酶抑制剂潜在靶点的免疫组织化学和分子分析
Clin Sarcoma Res. 2013 Mar 7;3(1):3. doi: 10.1186/2045-3329-3-3.
5
Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report.舒尼替尼联合质子束放疗治疗软骨肉瘤1例报告
J Med Case Rep. 2012 Jan 30;6:41. doi: 10.1186/1752-1947-6-41.
6
Time-specific blockade of PDGFR with Imatinib (Glivec®) causes cataract and disruption of lens fiber cells in neonatal mice.特定位点阻断 PDGFR 受体的伊马替尼（格列卫）可导致新生小鼠白内障和晶状体纤维细胞的破坏。
Virchows Arch. 2011 Mar;458(3):349-56. doi: 10.1007/s00428-010-1024-3. Epub 2010 Dec 23.